Table 3.

Anabolic–androgenic steroid cessation and post-cycle therapy

Likelihood of stopping anabolic–androgenic steroids in next 5 years	Respondents, n = 470 (%)
1 (Very unlikely)	135 (28.7)
2	138 (29.4)
3	96 (20.4)
4	48 (10.2)
5 (Very likely)	53 (11.3)
Worries about stopping anabolic–androgenic steroids	Respondents, n = 443 (%)
Nothing	82 (18.5)
Recovery of testosterone or fertility	232 (52.4)
Effects on body composition or physical performance	268 (60.5)
Access to NHS for advice	107 (24.2)
Quality of NHS advice	110 (24.8)
Effectiveness or purity of PCT	182 (41.1)
Other	20 (4.5)
Interest in participating in a research trial about post-cycle therapy	Respondents, n = 469 (%)
1 (Not at all interested)	156 (33.3)
2	76 (16.2)
3	92 (19.6)
4	42 (9.0)
5 (Very interested)	103 (22.0)
Where would be best to access National Health Service (NHS) prescribed post-cycle therapy?	Respondents, n = 470 (%)
Community e.g., harm prevention clinic or local pharmacy	206 (43.8)
GP surgery	109 (23.2)
NHS Specialist clinic e.g., endocrinology	47 (10.0)
Online service	138 (29.4)